Core Viewpoint - On February 26, brokerages provided target prices for listed companies, with notable increases for Hongsoft Technology, China Railway, and Yifan Pharmaceutical, showing target price increases of 47.71%, 34.96%, and 32.82% respectively, across the IT services, infrastructure, and chemical pharmaceutical industries [1][2]. Group 1: Target Price Increases - Hongsoft Technology received a target price increase of 47.71%, with a new target price of 71.27 CNY [3]. - China Railway's target price increased by 34.96%, with a new target price of 8.30 CNY [3]. - Yifan Pharmaceutical's target price rose by 32.82%, with a new target price of 17.40 CNY [3]. Group 2: Brokerage Recommendations - A total of 27 listed companies received brokerage recommendations on February 26, with China Railway, Bohui Paper, and Zhujiang Beer each receiving one recommendation [2]. - Bohui Paper's rating was upgraded from "Range Trading" to "Buy" by Guotai Junan Securities [5]. Group 3: Rating Adjustments - Two companies had their ratings downgraded: Baolong Technology from "Buy" to "Hold" by Tianfeng Securities, and Haiguang Information from "Buy" to "Range Trading" by Guotai Junan Securities [6][8]. - The companies involved in the downgrades were Baolong Technology and Haiguang Information [8]. Group 4: First Coverage - Six companies received first coverage on February 26, including Matrix Co. and Anfu Technology, both rated "Outperform" by Guotai Junan Securities [10]. - Other companies receiving first coverage included Aorite with a "Buy" rating from Zhongyou Securities, Delijia with a "Buy" rating from Dongwu Securities, and Hanguo Group with an "Increase" rating from Dongguan Securities [10].

www.leadleo.com 2025年中国真空泵机行业概览：外资 占据高端市场，国产化时代迎来多领 域渗透发展期 China Vacuum Pump Industry 中国真空ポンプ産業 概览标签：真空泵、通用设备制造业 2025/11 1 www.leadleo.com 400-072-5588 ©2025 LeadLeo 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均 系头豹研究院独有的高度机密性文件（在报告中另行标明出处者除外 ）。未经头豹研究院事先书面许可，任何人不得以任何方式擅自复制 、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述 约定的行为发生，头豹研究院保留采取法律措施，追究相关人员责任 的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹 "的商号、商标，头豹研究院无任何前述名称之外的其他分支机构， 也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 研究目的&摘要 研究目的 本报告为2025年中国真空泵行业概览报 告，将梳理中国真空泵行业的相关生产及 发展情况，对该行业的产业链，竞争格局 做出具体分析。 此研究将会回答的关键问题 ①中国真空泵 ...

河南省2025年医疗器械招标项目总计5061个，招标预算总金额约95.89亿元。相较于2024年，2025年招 标规模有所增加，其中招标项目从4572个增至5061个，增幅超10%，招标预算总金额从71.12亿元增至 94.98亿元，增幅超30%。（获取详细数据，请添加立方招采通客服微信：SK_lifangzct） 【大河财立方 记者 唐卫东】据立方招采通数据统计，2025年，河南省共有超过600家医疗机构及相关单 位发布招标公告，医疗器械招标及中标信息总计超8000条，医用耗材招标及中标信息总计超2000条。其 中，医疗器械单个项目超过1000万元的，招标项目201个，中标项目145个，郑州市在数量及金额方面都 远超其他城市。 孟州市第一人民医院新建项目医疗设备（第一批）及部分设备购置项目预算金额高达1.55亿元，是今年 预算金额最高的项目；新乡医学院第一附属医院3.0T磁共振购置项目中标金额为8256.5万元，在单个项 目中标金额中排在第1位；此外，还有多个大额项目进行分批采购。医用耗材招标呈季度梯度上升态 势，郑州、新乡、许昌三城领跑，检验类、影像类耗材成为采购热点。 医疗器械招标项目超5000个，郑大 ...

Core Viewpoint - The pharmaceutical and biotechnology sector is expected to experience valuation recovery driven by policy and industry resonance in 2025, with the sector's PE (TTM) rising from 31x as of September 30, 2025, indicating a positive investment outlook [1][35]. Group 1: Market Review - The pharmaceutical sector's PE (TTM) has fluctuated between 21x and 53x since 2015, with an average of 33x, and has shown signs of recovery since Q1 2025 after hitting a low in September 2022 [1][11][45]. - The market capitalization of pharmaceutical stocks held by equity funds was 12.2% in Q2 2025, reflecting a 1.8 percentage point increase and indicating a recovery trend [12][49]. Group 2: Global Economic Context - The return to a rate-cutting environment globally, particularly with the Federal Reserve's rate cut in September 2025, is favorable for innovative assets, while global aging trends are driving increased healthcare spending [2][36][56]. - China's pharmaceutical innovation is gaining momentum, with expectations of capturing a larger share of the global pharmaceutical market, thus enhancing the competitiveness of the domestic industry [2][36]. Group 3: Investment Thesis - The investment strategy is framed around a three-stage clinical value model: 1. "0→1" technological breakthroughs in innovative drugs and devices, enhancing domestic capabilities [2][36]. 2. "1→10" clinical validation with high-quality domestic drugs accelerating overseas licensing [2][36]. 3. "10→100" efficiency in the Chinese pharmaceutical supply chain, with CXO companies achieving stable growth through cost advantages [2][36]. Group 4: Recommended Companies - Key companies recommended for investment include Innovent Biologics (H), Eifang Biologics (U), Tianshili, WuXi AppTec (A+H), Prasis, Mindray Medical, United Imaging Healthcare, and Weisi Medical [3][37].

Market Performance - The pharmaceutical sector increased by 0.84% on February 25, 2025, outperforming the CSI 300 index by 0.24 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, other biological products (+2.39%), hospitals (+2.04%), and medical consumables (+1.58%) showed the best performance, while offline pharmacies (+0.32%), in vitro diagnostics (+0.33%), and medical research outsourcing (+0.34%) lagged behind [1] - Top three gainers in individual stocks were Changchun High-tech (+10.00%), Aidi Te (+9.03%), and Changshan Pharmaceutical (+8.87%); top three losers were Frontier Biotech (-4.09%), Baile Tianheng (-3.62%), and Shuoshi Biotech (-2.97%) [1] Industry News - Immedica announced that the FDA has accelerated the approval of Loargys for the treatment of hyperargininemia in patients aged 2 years and older with arginase 1 deficiency (ARG1-D), based on positive results from the Phase 3 PEACE trial [2] - The trial showed that the geometric mean of plasma arginine (pArg) in patients treated with Loargys decreased significantly from 354.0 μmol/L to 86.4 μmol/L by week 24 [2] - Loargys is a recombinant human arginase that can rapidly and sustainably lower plasma arginine and its toxic metabolites while improving clinical symptoms; it has already been approved in the EU and the UK [2] Company News - Sino Medical (688108) reported a revenue of 525 million yuan for 2025, a year-on-year increase of 14.53%, with a net profit attributable to shareholders of 47 million yuan, up 3057.05%, and a net profit of 34 million yuan after deducting non-recurring items, up 293.82% [3] - United Imaging (688271) announced a revenue of 13.821 billion yuan for 2025, a 34.18% increase year-on-year, with a net profit of 1.888 billion yuan, up 49.60%, and a net profit of 1.788 billion yuan after deducting non-recurring items, up 77.01% [3] - Huyou Pharmaceutical (688553) received notification from the FDA that its new drug applications for etoposide injection and fluorouracil injection have been approved, facilitating the company's expansion into the U.S. market [3] - Aibo Medical (688050) announced plans to acquire 68.31% of Demai Medical for 683 million yuan, with Demai Medical being a leading company in sports medicine; this acquisition will make it a subsidiary of Aibo Medical [3]

2026 年 02 月 25 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260225）：酶替代疗法 Loargys 获 FDA 批准 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 25/2/25 25/5/9 25/7/21 25/10/2 25/12/14 26/2/25 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260224）： Molbreevi 获 FDA 授予优先审评资 格>>--2026-02-25 <<太平洋医药日报（20260213）：安进 Inebilizumab 获欧盟批准>>--2026- 02-15 <<太平洋医药日报（20260212）：默沙 东 Keytruda 获 FDA 批准新适应症>>- -2026-02-15 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 电话： E-MAIL：zha ...

经济观察报实习记者田韫莘记者张英 上市后，联影医疗出现业绩波动。2023年，营收与利润保持增长，但2024年两项指标均下滑，营收同比 下滑9.73%，扣非净利润同比下滑39.32%。 对2025年业绩恢复增长的原因，联影医疗从国内、国外两方面进行了解释。 在国内市场，大规模医疗设备更新政策2025年进入常态化、专业化实施阶段，高端医学影像、放疗及基 层诊疗相关设备需求持续释放，行业整体规模较上年同期明显回升。联影医疗称，自身在国内市场占有 率持续提升并保持行业领先地位，2025年中国市场收入规模实现显著增长，经营质量与盈利能力同步增 强。 2月25日晚间，国产医疗影像龙头联影医疗(688271.SH)发布业绩快报，2025年营业总收入为138.21亿 元，同比增长34.18%，扣非净利润17.88亿元，同比增长77.01%。营收与扣非净利润的增幅均创上市以 来新高。 联影医疗成立于2011年，主要提供大型医学影像诊断与治疗设备、生命科学仪器。2022年8月，联影医 疗上市，创下当年科创板最大规模IPO。 近年来，联影医疗一直着力拓展海外业务。2023年其境外主营业务收入为16.59亿元，同比增长 53.97% ...

中金公司研报指出，联影医疗2025年收入138.21亿元（+34.18% YoY），归母净利润18.88亿元 （+49.60% YoY），收入端超我们预期，主要因高端产品放量较好且海外业务保持高增，利润端略低于 我们预期，主要因费用端投入超我们预期。招采复苏持续兑现，收入端实现强劲增长。利润端稳中有 进，关注高端产品及超声产线落地带来的利润改善预期。综合考虑公司长期发展竞争力兑现和短期板块 估值情况，基于DCF（WACC 7.1%，永续增长率2.0%）维持目标价170元（33%上行空间），维持"跑 赢行业"评级。 ...

摘要 ■ 投资逻辑 基于大模型对券商年度展望的全面解析 每年的年底到年初，各券商会密集发布关于总量、行业等年度报告。对投资者而言，难以整合大量研报信息从而提取共识点，此外分歧点也同样缺乏量化 对比。大模型工具的出现解决了这一难点，大模型可以帮助分析师快速完成研报数据预处理、观点精准抓取与分类；大模型通过确定共识点与分歧点的判 定规则，系统整合分散观点，量化呈现各券商对板块不同观点的支持率，清晰核心分歧维度。本次研究以大模型为核心分析工具，全面剖析2026年各大板 块年度展望，梳理宏观、策略、固收及七大细分行业的共识与分歧，为投资者提供高效精准的决策参考。 总量观点总结 对于总量观点，我们分别从宏观经济、年度策略、固定收益三个方面分别剖析了各券商分析师的年度展望。 在宏观经济方面，大多数券商认为随着"十五五"政策发力，2026年GDP目标为5%左右；CPI、PPI从低位逐步修复，国内通货膨胀的压力得到缓解；货币 政策维持适度宽松基调，流动性保持合理充裕；财政政策延续积极取向，赤字率维持合理高位；出口保持稳健，贸易顺差维持历史较高水平；国外环境虽 然出现波动，但整体风险可控。 作者：高智威、许坤圣 在年度策略方面 ...

午后算力芯片概念拉升，寒武纪涨近10%。消息面上，国产算力芯片龙头海光信息公告，预计一季度实 现归属于母公司所有者的净利润6.2亿元—7.2亿元，同比增长22.56%—42.32%。海外方面，英伟达最新 发布2026财年第四季度财报，营收、净利润及下一季度指引全面超越市场预期。 中信证券指出，当前中美双方各大云巨头均大幅加大AI相关资本开支：OpenAI 正在向投资者传达，公 司目前的目标是到 2030 年累计投入约6000亿美元的算力支出；字节跳动已初步规划2026年资本开支 1600亿元人民币，高于2025年约1500亿元人民币；阿里于2025年云栖大会同样表示，将在未来三年3800 亿元人民币的资本开支投入基础上，额外增加投入。国产算力中，超节点架构是国产算力建设实现后发 赶超的必经之路，云厂商与设备商正加速推进开放协议的适配，建议重点关注互联密度提升带来的价值 重估机遇，包括光通信、高速线模组、交换芯片及交换机、IDC等环节。 数据显示，截至2026年1月30日，上证科创板50成份指数(000688)前十大权重股分别为海光信息、中芯 国际、澜起科技、寒武纪、中微公司、芯原股份、金山办公、联影医疗、佰维 ...